Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives, based in India. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its products are exported to key regulated markets such as the United States (US), the European Union, and Japan.